Related Experiment Video
Updated: Jul 17, 2026
08:26
Development of Amelogenin-chitosan Hydrogel for In Vitro Enamel Regrowth with a Dense Interface
Published on: July 10, 2014
Chitosan-quinoxaline Schiff base hydroxyapatite composite with antimicrobial properties for bone regeneration
Abdelrahman Barakat1, Gameel A M Ehagali2, Shahira H El-Moslamy3
1Department of Chemistry, Faculty of Science (boys), Al-Azhar University, Nasr City, Cairo, 11884, Egypt. dr_abdelrahman@azhar.edu.eg.
Scientific Reports
|July 15, 2026
Summary
A novel chitosan-quinoxaline Schiff base hydroxyapatite composite was developed to combat implant-associated infections in bone regeneration. This infection-resistant material shows excellent biocompatibility and antimicrobial properties, paving the way for advanced bone repair therapies.
Area of Science:
- Biomaterials Science
- Materials Chemistry
- Orthopedic Surgery
Background:
- Implant-associated infections are a significant obstacle in bone regeneration, often leading to the failure of hydroxyapatite-based biomaterials.
- Developing infection-resistant materials is crucial for improving the long-term success of bone regeneration therapies.
Purpose of the Study:
- To synthesize and characterize a novel chitosan-quinoxaline Schiff base hydroxyapatite composite for bone regeneration.
- To evaluate the antimicrobial activity and biocompatibility of the developed composite system.
Main Methods:
- Synthesis of a sulfonated quinoxaline aldehyde (B6) and its covalent grafting onto chitosan via Schiff base condensation.
- Incorporation of chitosan-quinoxaline derivatives into hydroxyapatite to form composite systems (dH0-dH4).
- Characterization using FTIR, NMR, XRD, XPS, TGA, SEM-EDX, and BET; assessment of antimicrobial activity and cytotoxicity.
Main Results:
- Successful synthesis and characterization of the chitosan-quinoxaline Schiff base hydroxyapatite composite with enhanced thermal stability and a mesoporous architecture.
- The optimized dH2 composite demonstrated significant antimicrobial activity, inhibiting Bacillus cereus (89.65%) and Staphylococcus aureus (86.65%) biofilms.
- Excellent biocompatibility was observed, with >99% cell viability and high IC50 values in cytotoxicity assessments.
Conclusions:
- The developed chitosan-quinoxaline Schiff base hydroxyapatite composite is a multifunctional, infection-resistant platform.
- This novel biomaterial shows great promise for applications in bone regeneration, addressing the challenge of implant-associated infections.
